Almonertinib Therapy in Patients With Abnormal Liver Function After EGFR-TKI Treatment, or Almonertinib First-line Therapy in Patients With Basic Hepatopathy
NCT05662813
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
55
Enrollment
OTHER
Sponsor class
Conditions
Non-small Cell Lung Cancer
Interventions
DRUG:
Almonertinib
Sponsor
West China Hospital